COLLEGIUM PHARMACEUTICAL INC
COLLNASDAQTrading Snapshot
- Day Range
- $23.57 – $24.18
- 52-Week Range
- $21.43 – $50.79
- Volume (shares)
- 656,444
- Avg Volume (shares)
- —
- Shares Outstanding
- 32.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $781M
- Last Q Revenue
- $200M
- P/E Ratio
- 15.7
- P/S Ratio
- 1.0x
- EPS (TTM)
- $1.48
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −1.0%
COLLEGIUM PHARMACEUTICAL INC
COLL
StockOtter · stockotter.spaceAbout COLLEGIUM PHARMACEUTICAL INC
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership combines youth coach tr
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidate) CII in adults and
COLL vs. DSNKY: Which Stock Is the Better Value Option?
Investors interested in Medical - Drugs stocks are likely familiar with Collegium Pharmaceutical (COLL) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Collegium Pharmaceutical: Under 3x Cash Earnings After A Narrow Guidance Cut
Collegium Pharmaceutical is rated a high-risk Buy after a sharp guidance cut and stock drop, with the market pricing in an overly pessimistic scenario. ADHD drugs Jornay PM and AZSTARYS now account for over 30% of 2026 s